The Ozempic Blockbuster and the Mounjaro User

5 snips

Dec 7, 2024

Delve into the surprising claims from Danish scientists about semaglutide and the implications for weight loss. Explore concerns over trial transparency and the conflicts in pharmaceutical motivations. Follow personal journeys with GLP-1 medications like Mounjaro, highlighting significant transformations and behavioral changes. Engage in discussions around the mental health impact of dietary struggles and the importance of open conversations with healthcare professionals. This provocative exploration reflects on the complex dynamics of weight management today.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Scientists Question Higher Semaglutide Doses

Two senior Danish scientists questioned the use of higher Semaglutide doses for weight loss.
This was unsupported by Phase 2 trials, according to an article published the same month Ozempic got approved.

ANECDOTE

Scientists' Funding Source

The Danish scientists who criticized higher Semaglutide doses received large research grants from Novo Nordisk.
This raises questions about potential conflicts of interest but doesn't invalidate their expertise.

ANECDOTE

Another Scientist's Concerns

Another Danish scientist, head of the Danish Society for General Medicine, voiced concerns about Wegovy.
She highlighted Novo Nordisk's influence within the medical and research community, including an alleged advisory board offer she received.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

In 2017 two respected Danish Scientists claimed that higher dosages of the GLP1 Semaglutide, which had been planned as a treatment for Obesity, were not supported by the Clinical trials. I look at the timing of this article and their controversial statement. I search for the missing Phase II Ozempic Clinical trials and take a look at the Phase III Ozempic Trials on Diabetics and question the small amount of weight loss found alongside the large number of side effects. I also chat to Kevin about his surprising Mounjaro weight loss journey.

Contact

investigatingozempic@gmail.com

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

LINKS TO DOCUMENTS MENTIONED

Danish female Scientist Deadline show video

https://www.dr.dk/nyheder/indland/laegeformand-deadline-ringede-og-morgenen-efter-landede-der-et-tilbud-fra-novo

Annals of Translational Medicine Article

annals: https://atm.amegroups.org/article/view/17434/html

Ozempic Clinical Trials:

SUSTAIN 1

https://clinicaltrials.gov/study/NCT02054897?tab=results

SUSTAIN 2 clinical trial

https://clinicaltrials.gov/study/NCT01930188?term=%20NCT01930188&rank=1

SUSTAIN 3 clinical trial

https://clinicaltrials.gov/study/NCT01885208?term=NCT01885208&rank=1&tab=results

SUSTAIN 4 clinical trial

https://clinicaltrials.gov/study/NCT02128932?term=NCT02128932&rank=1

SUSTAIN 5 clinical trial

https://clinicaltrials.gov/study/NCT02305381?term=NCT02305381&rank=1

SUSTAIN 6 clinical trial - Heart Study

https://clinicaltrials.gov/study/NCT01720446?term=NCT01720446&rank=1